Multiple Sclerosis therapy licenced to US biotech Biogen by Dublin based Alkermes
Ireland-based Alkermes has licensed ALKS 8700 to US biotech Biogen. The drug is a novel, oral, small drug molecule that is currently in Phase III development for relapsing forms of multiple sclerosis. Under the terms of the deal, Biogen will receive exclusive, worldwide license to commercialise the experimental therapy, and will pay Alkermes a mid-teens